VERAXA Biotech (NASDAQ: VRXA) has reported new in vitro proof-of-concept data supporting its BiTAC-ADC platform, a technology designed to improve the selectivity of antibody-drug conjugates (ADCs) in cancer treatment. The company announced the findings as it prepares to engage with potential pharmaceutical and biotechnology partners during the BIO International Convention 2026 in San Diego (https://nnw.fm/APy2D).
The data demonstrated that VERAXA’s BiTAC-ADC technology was able to distinguish between breast cancer cells and healthy cells in laboratory studies and exhibited dose-dependent destruction of three-dimensional tumor cell spheroids. While the platform remains in early development, the results suggest potential for reducing off-target toxicity commonly associated with traditional ADCs.
VERAXA’s proprietary BiTAC approach is designed to improve the precision of antibody-based cancer therapies by activating therapeutic effects only in targeted tumor cells. The company is presenting its BiTAC-ADC and BiTAC-TCE platforms for potential strategic collaborations at the BIO convention. The company maintains a diversified oncology pipeline of antibody-based formats, including ADCs, T-cell engagers (TCEs), and other antibody-based formats.
VERAXA recently began trading on the NASDAQ Capital Market under the ticker symbol VRXA following the completion of its business combination with Voyager Acquisition Corp. The company’s newsroom is available at https://ibn.fm/VRXA.
Forward-looking statements in this article involve risks and uncertainties as detailed in the company’s SEC filings. For full terms of use and disclaimers, visit http://IBN.fm/Disclaimer.
